BioCorRx Inc. (BICX)

[seasailor]

"Randomized Trial of Long-Acting Sustained-Release Naltrexone Implant vs Oral Naltrexone or Placebo for Preventing Relapse to Opioid Dependence"
Link: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3614358/


Funding/Support: This study was supported by grants 1-R01-DA-017317 and KO5 DA-17009 from the National Institute on Drug Abuse (Dr Woody). Fidelity Capital provided naltrexone implants at reduced cost and placebo implants at no cost. The Zambon Group provided oral naltrexone at reduced cost.

"Methadone is a schedule I drug in Russia, and the Ministry of Health has not accepted Western data on the benefits of agonist maintenance therapy. This approach is similar in many ways to the United States from the mid- 1920s to late 1960s, when physicians could lose their licenses or be arrested and jailed if they used opioids to treat opioid addicts. However, unlike the United States during those years, Russia has committed significant resources to detoxification and residential treatment. For example, state-supported alcohol and drug treatment is provided in 138 dispensaries (115 of which have inpatient units) and 12 addiction hospitals with more than 25 000 beds in total and from 50 to 2000 beds per hospital depending on the region. In addition, several hundred commercial and nongovernmental organizations and more than 5600 psychiatrist-narcologists work in the addiction field (Evgenia Koshkina, MD, PhD, personal communication, September 2011). This treatment is readily available, as seen in the Table, where study patients averaged 4 to 5 prior treatment episodes."


NOTE at the bottom of the page before the references, look at the paid consultant's company:

"Financial Disclosure: Dr Krupitsky is a paid consultant to Alkermes, and Alkermes is providing extendedrelease injectable naltrexone for a study in which Dr Woody is an investigator."